Seelos's Amyotrophic Lateral Sclerosis Candidate, SLS-005 An Orphan Drug In Europe

by Vandana Singh, Benzinga Editor

May 27, 2021 8:28 AM | 23 seconds read | Make a Comment

Seelos Therapeutics Inc's SEEL Trehalose (SLS-005) has received Orphan Drug Designation for amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
Under the orphan designation, Seelos stands to benefit from several incentives such as protocol assistance, reduced regulatory fees, and market exclusivity.
Price Action: SEEL shares are up 2.9% at $3.17 during the premarket session on the last check Thursday.

Posted In: Biotech News Penny Stocks Health Care Small Cap FDA General Briefs European Medicines Agency (EMA)multiple sclerosis Orphan Drug Designation

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.